|1.||Jin, Jie: 6 articles (06/2015 - 01/2008)|
|2.||Wu, Depei: 5 articles (12/2015 - 05/2011)|
|3.||Liu, Limin: 4 articles (12/2015 - 01/2014)|
|4.||Zhang, Yanming: 4 articles (12/2015 - 01/2014)|
|5.||Huang, Jian: 4 articles (06/2015 - 01/2008)|
|6.||Tong, Yin: 4 articles (10/2013 - 01/2008)|
|7.||Li, Xiaoli: 3 articles (12/2015 - 03/2015)|
|8.||Qu, Qi: 3 articles (12/2015 - 03/2015)|
|9.||Lu, Hua: 3 articles (03/2015 - 10/2007)|
|10.||Rogalska, Aneta: 3 articles (01/2014 - 10/2008)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/01/1995 - "Aclarubicin is therefore considered a highly active drug for remission reinduction of previously treated children suffering from ANLL with an acceptable toxicity."
12/01/1987 - "Aclarubicin can produce a significant response rate in previously treated patients with acute myeloblastic leukemia and should be considered for study in initial therapy."
12/01/1987 - "Phase II study of aclarubicin in acute myeloblastic leukemia."
01/01/1987 - "In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals. "
06/01/1984 - "Phase I-II study of aclarubicin for treatment of acute myeloid leukemia."
07/01/1992 - "The clinical efficacy of aclarubicin, an anthracycline antibiotic, was studied in 48 patients with leukemia. "
08/01/1986 - "[Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A]."
01/01/1987 - "[Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas]."
08/01/1986 - "Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study."
12/01/1980 - "A phase II study of aclacinomycin A in acute leukemia in adults."
|3.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
03/01/2000 - "We have reported that low-dose aclarubicin (ACR) therapy is effective in some patients with myelodysplastic syndrome (MDS). "
12/01/1991 - "Low-dose aclarubicin has also been reported to be effective as differentiation therapy in some patients with myelodysplastic syndrome and atypical AML. "
01/01/1987 - "Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A."
01/01/1990 - "To study the therapeutic effect of low-dose aclarubicin (ACR), we carried out comparative treatment of 15 patients with myelodysplastic syndrome (MDS) and atypical leukemia using this drug. "
01/01/1990 - "Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin."
|4.||Neoplasm Metastasis (Metastasis)
09/01/1997 - "ACR-CH is designed to (a) adsorb a great amount of aclarubicin and desorb in a free state; (b) distribute a greater amount of ACR for a longer period of time selectively to the regional lymph nodes; (c) be decreased in the systemic toxicity; and (d) enhance its therapeutic effect on lymph node metastases. "
12/01/1991 - "Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice."
02/01/1993 - "From these results, it appears that the new dosage form of aclacinomycin A, ACR-CH, with superior therapeutic efficacy against lymph node metastases, can also enhance the immune response of regional lymph node cells. "
11/01/2001 - "[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT]."
09/01/1995 - "[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles]."
|5.||Breast Neoplasms (Breast Cancer)
01/01/1993 - "An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs."
01/01/1993 - "We conclude that aclarubicin is inactive in metastatic breast cancer at the dose and schedule used. "
01/01/1987 - "Combination chemotherapy with aclarubicin in metastatic breast cancer."
09/01/1985 - "Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial."
01/01/1987 - "Phase II study of aclarubicin in patients with breast cancer previously untreated with adriamycin."
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|4.||Etoposide (VP 16)
|7.||Dosage Forms (Dosage Form)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Absorbable Gelatin Sponge